Vomiting: when it is expected (first-dose reactions or early titration) and when it is a reason to stop and seek help are different. Occasional vomiting during titration is ordinary. Persistent vomiting or vomiting of a new character later in treatment warrants contact with your clinician.
Fatigue in the first month: how much is the drug and how much is intake — what changed since posts 61–83
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Constipation: common, manageable, and frequently under-reported because it is not dramatic. Increasing fibre and fluid intake helps. Over-the-counter management is usually effective. This is worth addressing proactively rather than waiting for it to worsen.
Coming back to post #61, because the follow-up matters more than the original answer.
Nausea: the most common side effect and the most dose- and titration-dependent one. It is usually most prominent in the first 24 to 48 hours after injection and attenuates as the dose is held stable. At each escalation step it often resets briefly before attenuating again.
Picking up post #61: that is the part I would want checked first.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
Lean mass loss: the rate of lean tissue loss depends on protein intake, resistance training volume, and total energy deficit. Adequate protein and maintaining training intensity both help preserve lean mass during weight reduction.
post #65 is right about the mechanism and I think understates the practical bit.
Hair shedding: telogen effluvium associated with rapid weight loss is reported. The timing usually correlates with the speed of weight change rather than the compound specifically. It is usually self-limiting.
I read post #65 twice before replying, because I had assumed the opposite.
Fatigue: commonly reported, frequently multifactorial. It is worth asking whether other factors have changed (sleep, training volume, diet adequacy, hydration) before attributing all of it to the compound. Some fatigue resolves with time; some persists.
On post #65 — agreed on the reasoning, with one qualification.
Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
post #69 answers the question as asked. The question underneath it is different.
Delayed gastric emptying: the mechanism behind much of the gastrointestinal side-effect profile. At extreme magnitudes, severe gastroparesis is a rare but serious complication. Distinguishing ordinary gastrointestinal effects from the rare severe end is a clinical judgement.
Gallbladder complications: rapid weight loss increases the risk of gallstone formation. The mechanism is not specific to this drug class. The risk is greatest in the first months when weight loss is most rapid.
Pancreatitis: a rare but serious event with a specific presentation (epigastric pain, back pain, elevated lipase). If this constellation of findings appears, stopping the drug and seeking immediate evaluation is appropriate. Do not interpret this as "likely" — it is rare — but recognize the pattern if it appears.
Recognition and grading: nausea ranges from "noticeable" to "limiting". Constipation ranges from mild to severe. Having language to describe the magnitude helps you track whether something is worsening or stable and helps your clinician understand what you are reporting.
On post #70 — agreed on the reasoning, with one qualification.
Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
This follows post #72 rather than contradicting it.
Timeline matters: onset, duration, pattern over days or weeks, relationship to injection and to meals all provide information that "I have nausea" does not. Posting those details gets better responses than reporting the symptom alone.
Nausea: the most common side effect and the most dose- and titration-dependent one. It is usually most prominent in the first 24 to 48 hours after injection and attenuates as the dose is held stable. At each escalation step it often resets briefly before attenuating again.
Vomiting: when it is expected (first-dose reactions or early titration) and when it is a reason to stop and seek help are different. Occasional vomiting during titration is ordinary. Persistent vomiting or vomiting of a new character later in treatment warrants contact with your clinician.
Picking up post #76: that is the part I would want checked first.
Injection site reaction: local erythema, nodules, or induration at injection sites is reported by some people. Site rotation, avoiding reinjection into the same area for weeks, and allowing areas that react to recover all reduce the frequency.
Coming back to post #78, because the follow-up matters more than the original answer.
Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
Pancreatitis: a rare but serious event with a specific presentation (epigastric pain, back pain, elevated lipase). If this constellation of findings appears, stopping the drug and seeking immediate evaluation is appropriate. Do not interpret this as "likely" — it is rare — but recognize the pattern if it appears.
This follows post #79 rather than contradicting it.
Gallbladder complications: rapid weight loss increases the risk of gallstone formation. The mechanism is not specific to this drug class. The risk is greatest in the first months when weight loss is most rapid.
Recognition and grading: nausea ranges from "noticeable" to "limiting". Constipation ranges from mild to severe. Having language to describe the magnitude helps you track whether something is worsening or stable and helps your clinician understand what you are reporting.
This topic was referenced in
- Vomiting: when it is expected and when it is a reason to stop — one year onPractice › Side effects · 23 replies
- Dizziness on standing and the electrolyte explanation — does this still hold?Practice › Side effects · 94 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Dizziness on standing and the electrolyte explanation
On the subject in the title: Dizziness on standing and the electrolyte explanation Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am asking rather…
|
+3 | 7 | 147 | 4mo |
|
Early satiety becoming a problem rather than a benefit
Early satiety becoming a problem rather than a benefit — setting out what I have, and where I think it stops being reliable. A question about technique rather than about dose. I have been doing the same thing…
|
+20 | 24 | 2.5k | 6mo |
|
Hair shedding at month three: mechanism and time course — the long version
Hair shedding at month three: mechanism and time course — the long version Writing it up because I had to work it out twice and would rather nobody else did. Reporting something rather than asking about it,…
|
+50 | 54 | 50k | 1d |
|
Why side effects reset at each escalation and that is not a failure
Why side effects reset at each escalation and that is not a failure — that is the question, and I have not found it answered plainly anywhere I have looked. I have read the maintained page on this and I still…
|
+3 | 7 | 11k | 14h |
|
[2026 update] Reflux appearing for the first time at a dose step
Posting this under the heading it deserves: Reflux appearing for the first time at a dose step Everything below is what sits behind that. Reporting something rather than asking about it, in case the pattern…
|
2 | 980 | 7mo |
Related topics — sharing the tags nausea, constipation, hair shedding
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Fibre intake when total intake falls, and the constipation link
Fibre intake when total intake falls, and the constipation link — setting out what I have, and where I think it stops being reliable. Longitudinal report with the method stated, because a number without a…
|
+61 | 66 | 12k | 15mo |
|
A side-effect grading scheme this community uses, and its limits — the long version
A side-effect grading scheme this community uses, and its limits — the long version — setting out what I have, and where I think it stops being reliable. Reporting something rather than asking about it, in…
|
+19 | 23 | 29k | 20mo |
|
Early satiety becoming a problem rather than a benefit
Early satiety becoming a problem rather than a benefit — setting out what I have, and where I think it stops being reliable. A question about technique rather than about dose. I have been doing the same thing…
|
+20 | 24 | 2.5k | 6mo |
|
Fatigue in the first month: how much is the drug and how much is intake
On the subject in the title: Fatigue in the first month: how much is the drug and how much is intake Working notes rather than a conclusion. A question about technique rather than about dose. I have been…
|
4 | 17k | 3mo | |
|
Vomiting: when it is expected and when it is a reason to stop — one year on
Vomiting: when it is expected and when it is a reason to stop — one year on Writing it up because I had to work it out twice and would rather nobody else did. Reporting something rather than asking about it,…
|
+19 | 23 | 49k | 18h |